Literature DB >> 9525969

Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin.

S W Pipe1, J A Morris, J Shah, R J Kaufman.   

Abstract

Factor VIII (FVIII) and factor V (FV) are homologous coagulation cofactors sharing a similar domain organization (A1-A2-B-A3-C1-C2) and are both extensively glycosylated within their B-domains. In mammalian cell expression systems, compared with FV, the FVIII primary translation product is inefficiently transported out of the endoplasmic reticulum. Here we show that FVIII is degraded within the cell by a lactacystin-inhibitable pathway, implicating the cytosolic 20 S proteasome machinery. Protein chaperones calnexin (CNX) and calreticulin (CRT) preferentially interact with glycoproteins containing monoglucosylated N-linked oligosaccharides and are proposed to traffic proteins through degradative and/or secretory pathways. Utilizing co-immunoprecipitation assays, intracellular FVIII was detected in association with CNX maximally within 30 min to 1 h following synthesis, whereas FV could not be detected in association with CNX. In contrast, both FVIII and FV displayed interaction with CRT during transit through the secretory pathway. B-domain deleted FVIII significantly reduced the CNX and CRT interaction, indicating the B-domain may represent a primary CNX and CRT interaction site. In the presence of inhibitors of glucose trimming, the interactions of FVIII with CNX, and of FVIII and FV with CRT, were significantly reduced whereas the secretion of FVIII, and not FV, was inhibited. In addition, transfection in a glucosidase I-deficient Chinese hamster ovary cell line (Lec23) demonstrated that both degradation and secretion of FVIII were inhibited, with little effect on the secretion of FV. These results support that CNX and CRT binding, mediated at least in part by the B-domain of FVIII, is required for efficient FVIII degradation and secretion. In contrast, FV does not require CNX interaction for efficient secretion. The results suggest a unique requirement for carbohydrate processing and molecular chaperone interactions that may limit the productive secretion of FVIII.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9525969     DOI: 10.1074/jbc.273.14.8537

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  The propeptide of macrophage inhibitory cytokine (MIC-1), a TGF-beta superfamily member, acts as a quality control determinant for correctly folded MIC-1.

Authors:  A R Bauskin; H P Zhang; W D Fairlie; X Y He; P K Russell; A G Moore; D A Brown; K K Stanley; S N Breit
Journal:  EMBO J       Date:  2000-05-15       Impact factor: 11.598

2.  Quality control of transmembrane domain assembly in the tetraspanin CD82.

Authors:  K S Cannon; P Cresswell
Journal:  EMBO J       Date:  2001-05-15       Impact factor: 11.598

Review 3.  From the ER to the golgi: insights from the study of combined factors V and VIII deficiency.

Authors:  W C Nichols; D Ginsburg
Journal:  Am J Hum Genet       Date:  1999-06       Impact factor: 11.025

4.  The cotranslational maturation of the type I membrane glycoprotein tyrosinase: the heat shock protein 70 system hands off to the lectin-based chaperone system.

Authors:  Ning Wang; Robert Daniels; Daniel N Hebert
Journal:  Mol Biol Cell       Date:  2005-06-15       Impact factor: 4.138

5.  Expression of human coagulation factor VIII in a human hybrid cell line, HKB11.

Authors:  Baisong Mei; Yaoqi Chen; Jianmin Chen; Clark Q Pan; John E Murphy
Journal:  Mol Biotechnol       Date:  2006-10       Impact factor: 2.695

6.  Peptide-based interactions with calnexin target misassembled membrane proteins into endoplasmic reticulum-derived multilamellar bodies.

Authors:  Vladimir M Korkhov; Laura Milan-Lobo; Benoît Zuber; Hesso Farhan; Johannes A Schmid; Michael Freissmuth; Harald H Sitte
Journal:  J Mol Biol       Date:  2008-03-04       Impact factor: 5.469

7.  Coagulation Factor Activities Changes Over 5 Days in Thawed Fresh Frozen Plasma Stored at Different Initial Storage Temperatures.

Authors:  Siti Salmah Noordin; Faraizah Abdul Karim; Wan Mohd Zahiruddin Bin Wan Mohammad; Abdul Rahim Hussein
Journal:  Indian J Hematol Blood Transfus       Date:  2017-10-07       Impact factor: 0.900

8.  Advancements in gene transfer-based therapy for hemophilia A.

Authors:  Christopher B Doering; H Trent Spencer
Journal:  Expert Rev Hematol       Date:  2009-12       Impact factor: 2.929

9.  Factor VIII and vWF deficiency in STT3A-CDG.

Authors:  Irene J Chang; Heather M Byers; Bobby G Ng; John Lawrence Merritt; Reid Gilmore; Shiteshu Shrimal; Wei Wei; Yuan Zhang; Amanda B Blair; Hudson H Freeze; Bin Zhang; Christina Lam
Journal:  J Inherit Metab Dis       Date:  2019-01-30       Impact factor: 4.982

Review 10.  Blood coagulation factor VIII: An overview.

Authors:  G M Bhopale; R K Nanda
Journal:  J Biosci       Date:  2003-12       Impact factor: 1.826

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.